Learning Objectives:

• Review the therapeutic need for better treatments for -7/del(7q) myeloid neoplasms.
• Discuss the application of induced pluripotent stem cells (iPSCs) to model hematopoietic diseases and as a platform for drug development.
• Present plans to generate isogenic iPSCswith frequent co-mutations with CUX1 haploinsufficiency.

Session date: 
10/07/2024 - 12:00pm to 1:00pm CDT
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Please login or create an account to proceed.
Speaker Name: 
Joseph Cannova, MD, PhD